Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zanapezil SCHEMBL29366424 | 1.00 | ACHE (1.00) | ACHE | |
| SCHEMBL9204959 | 0.99 | ACHE (1.00) | ACHE | |
| SCHEMBL9209651 | 0.97 | ACHE (1.00) | ACHE | |
| Zanapezil SCHEMBL1232174 | 0.95 | ACHE (0.91) | ACHE | |
| Zanapezil SCHEMBL1232176 | 0.95 | ACHE (0.91) | ACHE | |
| Fumaric Acid SCHEMBL9203761 | 0.95 | ACHE (0.91) | ACHE | |
| Fumaric Acid SCHEMBL9203739 | 0.95 | ACHE (0.91) | ACHE | |
| Fumaric Acid SCHEMBL9200365 | 0.93 | ACHE (0.91) | ACHE | |
| Fumaric Acid SCHEMBL9200378 | 0.93 | ACHE (0.91) | ACHE | |
| SCHEMBL9201840 | 0.92 | ACHE (1.00) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042939-A1 | Methods and Compositions Using Cholinesterase Inhibitors | EISAI CO., LTD. (JP) | 2009-02-12 | — | — | US | claimed |
| US-20090042940-A1 | METHODS AND COMPOSITIONS USING CHOLINESTERASE INHIBITORS | EISAI CO., LTD. (JP) | 2009-02-12 | — | — | US | claimed |
| US-20060018839-A1 | Methods and compositions using cholinesterase inhibitors | EISAI CO., LTD. (JP) | 2006-01-26 | — | — | US | claimed |
| WO-2005074535-A2 | CHOLINESTERASE INHIBITORS FOR SPINAL CORD DISORDERS | EISAI CO., LTD. (JP) | 2005-08-18 | — | — | WO | claimed |
| WO-2003092606-A2 | CHOLINESTERASE INHIBITORS TO PREVENT INJURIES CAUSED BY CHEMICALS | EISAI CO., LTD. (JP) | 2003-11-13 | — | — | WO | claimed |
| EP-0952826-B1 | IDEBENONE CONTAINING COMBINATION AGENT FOR TREATING ALZHEIMER'S DISEASE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-11-14 | — | — | EP | claimed |
| EP-0487071-B1 | Condensed heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-07-05 | — | — | EP | claimed |
| US-5273974-A | Condensed heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-12-28 | — | — | US | claimed |
| EP-0487071-A1 | Condensed heterocyclic compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1992-05-27 | — | — | EP | claimed |
| JP-10203966-A | — | — | None | — | — | JP | disclosed |
| JP-5140149-A | — | — | None | — | — | JP | disclosed |
| CN-122071471-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-22 | — | — | CN | disclosed |
| CN-122010946-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-12 | — | — | CN | disclosed |
| CN-122010945-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-12 | — | — | CN | disclosed |
| EP-0901787-A1 | Stabilized pharmaceutical composition | Takeda Chemical Industries, Ltd. (JP) | 1999-03-17 | — | — | EP | disclosed |
| JP-H10203966-A | SUSTAINED RELEASE MICROCAPSULE AND ITS PRODUCTION | TAKEDA CHEM IND LTD | 1998-08-04 | — | — | JP | disclosed |
| EP-0487071-B1 | Condensed heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-07-05 | — | — | EP | disclosed |
| US-5273974-A | Condensed heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-12-28 | — | — | US | disclosed |
| JP-H05140149-A | CONDENSED HETEROCYCLIC DERIVATIVE | TAKEDA CHEM IND LTD | 1993-06-08 | — | — | JP | disclosed |
| EP-0487071-A1 | Condensed heterocyclic compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1992-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060018839-A1 | Methods and compositions using cholinesterase inhibitors | PSEN1, BACE1, PSENEN | ACHE 26/4885 |
| US-20090042939-A1 | Methods and Compositions Using Cholinesterase Inhibitors | PSEN1, BACE1, PSENEN | ACHE 26/4885 |
| US-20090042940-A1 | METHODS AND COMPOSITIONS USING CHOLINESTERASE INHIBITORS | PSEN1, BACE1, PSENEN | ACHE 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.